Home
Duchenne
Categories
Care Guidelines
Press Releases
Approved Therapies
Researches
Editorials
Family Stories
Our Tools
Exon Check Tool
Clinical Trials
Active Studies
Trial Statistics
Trials Map
Pipeline
Search
About Us
Contact
APPs
Privacy Policy
type here...
Search
Instagram
Facebook
Twitter
Bluesky
Home
Duchenne
Duchenne MD
What is Duchenne?
Genetic Causes
Creatine Kinase (CK)
Genetic Testing
Prenatal Testing
Becker MD
DMD vs BMD
NSAA Assessment
Genetic
Genetic Counseling
Dystrophin Gene
Genetic Variants
Exon Deletion
Duchenne Carriers
Nucleotides in DMD
Isoforms in DMD
What is Exon Skipping
Care Guidelines
Newly Diagnosed
Neuromuscular Team
Respiratory Devices
BiPAP Machine
Ankle Foot Orthosis
Rhabdomyolysis
Power Wheelchair
Traveling with DMD
Health Guidelines
Psychological Support in DMD
Nutrition in DMD
Nutraceuticals
Respiratory Health
Dental Health
Surgery & Anesthesia
Swallowing Difficulty
Steroids (Cortisone)
Categories
Care Guidelines
Press Releases
Approved Therapies
Researches
Editorials
Family Stories
Our Tools
Exon Check Tool
Clinical Trials
Active Studies
Trial Statistics
Trials Map
Pipeline
WhatsAPP
Home
Tags
Del-zota
Del-zota
Editorials
7 Breakthrough DMD Research Programs That Could Transform Duchenne Treatment in 2026
Research
Del-Zota SAFARI44 Phase 3 Trial: A New Exon 44 Skipping Study for Duchenne Muscular Dystrophy
Research
Del-Zota Phase 3 SAFARI44 Clinical Trial for Duchenne Muscular Dystrophy: Study Design, Data, and Clinical Significance
Press Releases
Del-Zota Clinical Trial Begins in the US in Participants with DMD Mutations Amenable to Exon 44 Skipping
Press Releases
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota (Exon 44 Skipping)
Press Releases
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
Editorials
Del-Zota DMD RNA Therapy from Avidity Biosciences Reverses the Progression of Disease
Press Releases
Del-zota (Exon 44 Skipping Therapy) Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in Phase 1/2 Trial
Press Releases
FDA Designates Avidity Biosciences’ Delpacibart Zotadirsen (del-zota) as a Breakthrough Therapy for the Treatment of DMD in Individuals with Mutations That Allow for Exon...
1
2
Page 1 of 2
Popular
Frequently Asked Questions About Elevidys Used for DMD
Can Ekinci
-
August 21, 2026
Must Read
Press Releases
RGX-202 Duchenne Gene Therapy Shows NSAA Improvement and Microdystrophin Expression — But Important Biomarker Data Missing
Editorials
CRISPR GuideX Tool: hfCas12Max in CRISPR-Based Therapeutics
Care Guidelines
Breathing Exercises in Duchenne Muscular Dystrophy: Respiratory Therapy, Pulmonary Care & Lung Support
EN
AR
ZH
FR
DE
HI
RU
PT
ES
TR